MentalHealth.com Acquires Provider of Mental Health Resources and Clinical Guidelines
Founded in 1996, PsychGuides.com has been a longstanding provider of research-based mental health information, serving clinicians, policymakers, and patient advocates. Committed to advancing evidence-based care, it has collaborated with leading organizations, including Abbott Laboratories, Janssen Pharmaceutica, Solvay Pharmaceuticals, and Bristol Myers Squibb, to develop and distribute practical clinical guidelines that enhance mental health treatment and decision making.
'As mental health faces a pivotal moment driven by unprecedented demand, investing in high-quality resources that support informed decisions is essential to helping people regain well-being,' said Daniel Rivette, CEO and Co-Founder of MentalHealth.com. 'By integrating its guidelines and research-backed content into our platform, PsychGuides.com further enhances our reach and deepens our connection with those seeking support.'
This acquisition builds on a series of milestones for MentalHealth.com, including the acquisition of MentalHelp.net, the introduction of the MentalHealth.com Wellness Portal, and the launch of the Mental Health Network.
In the coming months, MentalHealth.com will announce key partnerships and acquisitions, along with new additions to its Venture Advisory, Clinical Affairs, and Public Oversight Teams, further reinforcing its mission to develop the world's most intelligent mental health technology.
To learn more about MentalHealth.com and its vision to support the mental health of one billion people, please visit: https://www.mentalhealth.com/vision
About MentalHealth.com
MentalHealth.com is a health technology company guiding people towards self-understanding and connection. The platform provides reliable resources, accessible services, and nurturing communities. Its purpose is to educate, support, and empower people in their pursuit of well-being.
Contact InformationHelena Georgiou 1-800-834-8587
SOURCE: MentalHealth.com, LLC
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
3 hours ago
- Miami Herald
Private Practices Are Being Squeezed by Med Spas and Hospital Systems, Dr. Meegan Gruber Warns Patients Must Put Safety First
Med spas together with hospital systems have started compressing private practices; Dr. Meegan Gruber urges patients to prioritize safety. TAMPA, FLORIDA / ACCESS Newswire / August 13, 2025 / Board-Certified Plastic Surgeon Dr. Meegan Gruber, MD, PhD, has launched an alert about the fast transformation of private practice ownership from physicians to large hospital systems and fast-growing med spas. The AMA conducted a benchmark survey which revealed that private practice physicians decreased from 60.1% in 2012 to 42.2% in 2024. Patients require ongoing medical care with personal physician supervision. The current market dynamics override medical expertise when it comes to determining both the delivery sites and methods of aesthetic care, according to Dr. Gruber. The medical landscape has transformed into a hospital and corporate employment-based structure -- a national analysis by the Physicians Advocacy Institute and Avalere found hospital and corporate employment rates reached 77.6% by January 2024. The same study indicates hospital employment increased to 55.1% while corporate employment reached 22.5% because of intense consolidation, which weakens patient-physician decision-making. Med spas have both proliferated in numbers and generated substantial revenue growth during the same period. Medical spas in the United States now operate above $17 billion annually while their market grows at a rate exceeding $1 billion yearly, according to the American Med Spa Association. The American Med Spa Association reports that the medical spa industry now generates $17 billion in revenue annually and adds $1 billion each year to its market value. New medical spa establishments increased by 18% during 2023, according to recent data. Medical standards that lack uniformity will produce inconsistent treatment results according to Dr. Gruber. Multiple states experienced hospitalizations because federal investigations revealed multiple cases of counterfeit botulinum toxin and mishandled injections in non-regulated medical settings. Price and convenience will never replace the importance of medical training and established protocols, according to Dr. Gruber. Patients should verify the identity of the procedure performer and the supervising physician's board certification and confirm emergency readiness at the facility. She suggests patients check for ABMS-recognized board certification in plastic surgery and insist on meeting the surgeon personally and verify where they source injectables. Dr. Gruber provides awake surgery under local anesthesia to qualified candidates as an option that reduces general anesthesia exposure and enables real-time team communication. She stated that the patient needs to be the correct choice while the procedure needs to be appropriate for the patient and the treatment must occur in an appropriate environment. At Gruber Plastic Surgery patients can discover more information about physician-led care that maintains continuity and learn about awake surgery and schedule a safety oriented consultation by contacting us. About Gruber Plastic Surgery Gruber Plastic Surgery, located in Tampa, FL, is led by Dr. Meegan Gruber, Ph.D., board-certified plastic surgeon renowned for her pioneering work in awake plastic surgery. Dr. Gruber, also the star of "Awake Surgery," which you can stream today on TLC GO, HBO MAX, Hulu, Discovery+, and other streaming platforms, integrates advanced techniques and cutting-edge technology to deliver safe, comfortable, and natural-looking results with minimized recovery time. Specializing in awake surgeries, the clinic offers a range of state-of-the-art procedures. Dr. Gruber is committed to innovation and education, ensuring precision and safety in every treatment, while enhancing patient confidence through individualized care and surgical expertise. Contact Information Jay Saint info@
Miami Herald
a day ago
- Miami Herald
Veterinary Referral Center of Central Oregon Expands Life-Saving Treatment Options With Extracorporeal Therapies
Now Offering Veterinary Hemodialysis, Therapeutic Plasma Exchange, and Hemoperfusion BEND, OR / ACCESS Newswire / August 12, 2025 / The Veterinary Referral Center of Central Oregon (VRCCO) is proud to announce the addition of advanced Extracorporeal Therapies, including Hemodialysis, Therapeutic Plasma Exchange, and Hemoperfusion, to its suite of specialized veterinary services. VRCCO is honored to be among the few facilities in the US to offer these cutting-edge treatments that provide new hope for pets suffering from acute kidney injuries, chronic kidney disease, immune-mediated diseases, and life-threatening toxicities. Hemodialysis serves as an "artificial kidney" by filtering a pet's blood to remove harmful substances such as waste, toxins, and excess fluids. While it does not directly heal the kidneys, it provides a vital window of time for recovery, while significantly improving comfort and quality of life for the pet during this critical period. Hemodialysis is most commonly used for acute kidney injuries, severe electrolyte imbalances, fluid overload, and certain toxicities. Therapeutic Plasma Exchange (TPE) is a procedure designed to remove harmful substances from a pet's plasma, replacing it with donor plasma. This therapy is particularly effective in managing severe immune-mediated conditions such as immune-mediated hemolytic anemia (IMHA) and myasthenia gravis, as well as certain toxicities. Pets may experience rapid improvement, particularly with immune-mediated diseases that are unresponsive to conventional treatments. Hemoperfusion involves filtering a pet's blood through a cartridge containing activated charcoal or similar materials to adsorb toxins. This technique is especially valuable in cases of NSAID overdoses (e.g., ibuprofen, carprofen) or exposure to other harmful substances where no antidote exists. Treatments are generally completed within 2-4 hours, and a single session is often sufficient if administered before organ damage occurs. VRCCO utilizes the same advanced dialysis machines and materials used in human medicine, ensuring the highest standards of care. Throughout treatments, patients are continuously monitored for vital parameters including blood clotting times, fluid balance, hematocrit, electrolytes, and cardiac health, with personalized attention from their care team. Pet Parents should also be aware of the following while considering these therapies: Comfort & Compassionate Care: Dialysis treatments are not painful. Pets rest comfortably on soft bedding under the continuous care and observation of VRCCO's specialized team. Sedation is rarely Size & Suitability: Most companion animals, regardless of size, can be safely treated. VRCCO's in-house blood bank ensures the availability of transfusions if & Expectations: Treatment outcomes are highly variable and depend on the severity and cause of the condition. Some pets may require only a few treatments, while others may need ongoing Intervention is Critical: Starting dialysis before severe complications arise, such as fluid overload or organ dysfunction, dramatically improves the likelihood of a positive outcome. The Veterinary Referral Center's board-certified specialists encourage pet parents and referring veterinarians to consult with them to determine whether these therapies are appropriate for individual cases. In many situations, time is a critical factor and early intervention can be life-saving. To learn more about Extracorporeal Therapies or VRCCO's comprehensive specialty services, please contact the Veterinary Referral Center of Central Oregon at 541-209-6960 or info@ Contact Information Katie Sedivec Marketing Directormarketing@ SOURCE: Veterinary Referral Center of Central Oregon press release
Miami Herald
a day ago
- Miami Herald
MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
Manuscript accepted for publication in Frontiers in Pharmacology, "Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagonism" details Ketamir-2's superior performance in two validated neuropathic pain models and supports advancement to Phase 2a clinical trials by year-end 2025. MIAMI, FL / ACCESS Newswire / August 12, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the acceptance of a second peer-reviewed manuscript describing its lead oral drug candidate, Ketamir-2, in Frontiers in Pharmacology. The newly accepted publication reports that Ketamir-2 outperformed ketamine, pregabalin, or gabapentin-depending on the comparator used-in restoring sensory function and reversing pain behaviors across two gold-standard rodent models of neuropathic pain. The findings build on MIRA's first publication characterizing Ketamir-2's clean pharmacology and favorable safety profile and align with the Company's plan to initiate a Phase 2a trial in neuropathic pain by year-end 2025. Market Opportunity Neuropathic pain represents a significant and underserved market across North America. Epidemiology suggests approximately 7-10% of the population experiences neuropathic pain; in North America, this equates to approximately 36-51 million people across the U.S., Canada, and Mexico. According to Precedence Research, the global neuropathic pain market is valued at approximately $7.97 billion in 2024 and is projected to reach $16.79 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.73%. North America accounts for a significant share of this market, representing an estimated $3.7-3.9 billion annually today. The U.S. neuropathic pain market is estimated at $2.79 billion in 2024 and is projected to reach $5.92 billion by 2034, growing at a CAGR of 7.80% over the same period. Growth is expected to be driven by rising prevalence of diabetes, cancer survivorship, and aging-related nerve damage, underscoring the large and expanding commercial potential for novel treatments such as Ketamir-2. Ketamir-2's differentiated mechanism, oral bioavailability, and superior performance in gold-standard preclinical models position it as a potential next-generation, non-opioid treatment option in this multi-billion-dollar and rapidly growing market. Key Findings from the Publication Chung Model (sciatic nerve ligation in rats)Male rats: Ketamir-2 restored sensory thresholds toward baseline, while ketamine-tested as the comparator-showed no measurable rats: Ketamir-2 outperformed both pregabalin and gabapentin, delivering greater and more consistent restoration of normal sensory (PTX)-Induced Neuropathy in MiceGabapentin was the sole comparator in this chemotherapy-induced neuropathy model. Ketamir-2 produced more complete normalization of pain sensitivity in both male and female cohorts, while gabapentin provided only partial or inconsistent Across Genders and SpeciesDespite differences in baseline pain sensitivity between male and female animals, Ketamir-2 demonstrated clear and significant therapeutic benefit in every cohort tested. Mechanistic Differentiation Ketamir-2 is a new molecular entity that selectively binds to the PCP site of the NMDA receptor with low affinity and shows no significant interaction with over 40 other receptor systems, including serotonin, dopamine, and opioid receptors. This combination of selectivity, oral bioavailability, and demonstrated efficacy in gold-standard models suggests the potential for a differentiated, next-generation therapeutic option in neuropathic pain. "The acceptance of this second peer-reviewed publication is another important milestone for our Ketamir-2 program," said Erez Aminov, CEO of MIRA. "The data clearly demonstrate superior and more consistent pain relief compared to leading neuropathic pain drugs, within the specific models tested. This provides additional confidence as we advance Ketamir-2 toward Phase 2a clinical evaluation and continue to explore its potential in broader CNS applications." "The robust reversal of pain sensitivity observed in these well-validated preclinical models-whether compared to ketamine, pregabalin, or gabapentin-further supports Ketamir-2's potential as a differentiated, orally administered treatment for neuropathic pain," added Dr. Itzchak Angel, Chief Scientific Advisor. "Given the limited number of effective oral treatments for this indication, Ketamir-2's profile is especially compelling." Clinical Development Update Phase 1 Trial Progressing: The ongoing Phase 1 trial of Ketamir-2 in Israel is on schedule, with no safety concerns reported to date and the single ascending dose portion nearing 2a by Year-End: MIRA plans to submit a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration (FDA) in Q4 2025 as an advanced development version to its active IND, with the goal of initiating the study in neuropathic pain by Beyond Neuropathic Pain: With its clean pharmacology and oral bioavailability, Ketamir-2 is also being explored for potential applications in depression, anxiety, post-traumatic stress disorder (PTSD), and as a topical formulation for localized pain conditions. The full publication will be available upon release at: About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals
